Suntory Limited

Suntory Holdings Limited

Cerebos Pacific Limited

Nobuo Tsuruoka

Hiroshi Nakazato

Masafumi Tsujimoto

Tatsuya Kurihara

Nozomi Yamaguchi

Nobuhiro Ishida

Kenju Miura

Yoshinori Beppu

Fuyuki Iwasa

Kozo Yamaichi

Shoji Tanaka

Eiichiro Ono

Hajime Komura

Yayoi Wada

Hiroshi Watanabe

Kenji Arima

Katsuya Nagai

Shigekazu Matsukura

Tatsuro Nishihara

Hirofumi Kouda

The present invention aims to provide antidementia agents which are free from the problem of side effects and are excellent in safety. The present invention also aims to provide agents for improving learning and memory which are useful for improvement of learning and memory and can be ingested continuously. The present invention provides antidementia agents and agents for improving learning and memory, each comprising a cyclic dipeptide with the 2,5-diketopiperazine structure as an active ingredient.

Learning and memory improver

The present invention aims to provide antidepressants which are free from the problem of side effects and are excellent in safety. The present invention also aims to provide learning motivation improvers which are useful for improvement of learning motivation and can be ingested continuously. The present invention provides antidepressants and learning motivation improvers, each comprising a cyclic dipeptide with the 2,5-diketopiperazine structure as an active ingredient.

Learning motivation improvers

The object of the present invention is to provide-derived monoterpene glycosyltransferase and a method for producing a monoterpene glycoside by means of this enzyme. The present invention provides-derived monoterpene glycosyltransferase and a method for producing a monoterpene glycoside by means of this enzyme. The present invention provides a transformant transformed with a gene for-derived monoterpene glycosyltransferase and a method for producing such a transformant.

Monoterpene glycosyltransferase originating from hop and method for using same

The object of the present invention is to provide a novel method for producing a terpene 8-glycoside. The present invention provides a method for producing a terpene 8-glycoside by means of glycosyltransferase acting on the 8-position of terpenes. The present invention provides a transformant transformed with a gene for the glycosyltransferase acting on the 8-position of terpenes and a method for producing such a transformant. The present invention provides a plant modified to suppress the expression of a protein having glycosylation activity on the 8-position of a monoterpene compound.

Method for utilizing monoterpene glycosyltransferase

There is provided a pharmaceutical agent, food, or beverage for treating or preventing a disease or condition that can be ameliorated by inhibiting serotonin reuptake, comprising a clinically-effective amount of (1S,3S)-1-methyl-1,2,3,4-tetrahydro-&#x3b2;-carboline-3-carboxylic acid.

Pharmaceutical, food or beverage having inhibitory activity on serotonin transporter

It is intended to provide a safe composition for treating a disease or condition relating to autonomic nervous activity which has an autonomic nervous control effect; in particular, an effect of enhancing parasympathetic nervous activity. Thus, a medicinal composition, a food or a drink containing L-phenyl lactic acid and/or D-phenyl lactic acid and having an autonomic nervous control effect is provided.

Medicinal composition, food or drink having effect of enhancing parasympathetic nervous activity

A novel megakaryocyte differentiation factor, for example, consisting essentially of SEQ ID NO: 30; DNA coding for the megakaryocyte differentiation factor, an expression vector comprising the DNA, a host transformed with the expression vector, and a process for production of the megakaryocyte differentiation factor using the host. The megakaryocyte differentiation factor accelerates differentiation of megakaryocytes in the presence of IL-3, and acts as a thrombopoietin, and therefore an effective medicament to various diseases involving a decrease in platelete.

Megakaryocyte differentiation factor

DNA encoding megakaryocyte differentiation factor

The present invention provides novel megakaryocyte differentiation factors, which are useful as therapeutic agents due to their accelerating effects on the differentiation of megakaryocytes and their thrombopoietic effects. The megakaryocyte differentiation factors of the present invention include the megakaryocyte differentiation factor having the amino acid sequence shown in SEQ ID NO: 34. The present invention also provides DNA coding for the megakaryocyte differentiation factors of the present invention, expression vectors containing the DNA, hosts transformed with the expression vectors, and processes for production of the megakaryocyte differentiation factors using transformed hosts. The present invention further provides specific antibodies to the megakaryocyte differentiation factors of the present invention.

Antibodies specific for megakaryocyte differentiation factor

Anti-HBS antibody genes and expression plasmids therefor

Disclosed is a human TNF derivative with a reduced tendency to cause adverse side effects that is obtained by replacing the 31st and 32nd arginine residues from the N-terminal of the amino acid sequence of human TNF, which has a potential for causing serious adverse effects, with asparagine residue and threoine residue, respectively, as well as a method of preparing the same utilizing recombinant DNA technology.

Growing community of inventors

Osaka, Japan

Nobuo Tsuruoka